7787 related articles for article (PubMed ID: 1450992)
1. [Targeting of tumor cells by low density lipoproteins: principle and use of ellipticin derivatives].
Favre G
C R Seances Soc Biol Fil; 1992; 186(1-2):73-87. PubMed ID: 1450992
[TBL] [Abstract][Full Text] [Related]
2. Uptake of low-density lipoprotein by malignant cells--possible therapeutic applications.
Vitols S
Cancer Cells; 1991 Dec; 3(12):488-95. PubMed ID: 1840290
[TBL] [Abstract][Full Text] [Related]
3. Preparation of drug-low density lipoprotein complexes for delivery of antitumoral drugs via the low density lipoprotein pathway.
Lundberg B
Cancer Res; 1987 Aug; 47(15):4105-8. PubMed ID: 3607752
[TBL] [Abstract][Full Text] [Related]
4. Comparative study of the incorporation of ellipticine-esters into low density lipoprotein (LDL) and selective cell uptake of drug--LDL complex via the LDL receptor pathway in vitro.
Samadi-Baboli M; Favre G; Bernadou J; Berg D; Soula G
Biochem Pharmacol; 1990 Jul; 40(2):203-12. PubMed ID: 2375762
[TBL] [Abstract][Full Text] [Related]
5. Low-density lipoprotein for delivery of an acrylophenone antineoplastic molecule into malignant cells.
Lestavel-Delattre S; Martin-Nizard F; Clavey V; Testard P; Favre G; Doualin G; Houssaini HS; Bard JM; Duriez P; Delbart C
Cancer Res; 1992 Jul; 52(13):3629-35. PubMed ID: 1617635
[TBL] [Abstract][Full Text] [Related]
6. [Vectorization of antineoplastic drugs by low density lipoproteins: incorporation of acyl celiptium and metabolism of complexes in the cellular receptor of human fibroblasts].
Samadi-Baboli M; Favre G; Soula G
Bull Cancer; 1989; 76(8):853-7. PubMed ID: 2620112
[No Abstract] [Full Text] [Related]
7. Stable incorporation of a lipophilic daunorubicin prodrug into apolipoprotein E-exposing liposomes induces uptake of prodrug via low-density lipoprotein receptor in vivo.
Versluis AJ; Rump ET; Rensen PC; van Berkel TJ; Bijsterbosch MK
J Pharmacol Exp Ther; 1999 Apr; 289(1):1-7. PubMed ID: 10086980
[TBL] [Abstract][Full Text] [Related]
8. Prolonged serum half-life of antineoplastic drugs by incorporation into the low density lipoprotein.
de Smidt PC; van Berkel TJ
Cancer Res; 1990 Dec; 50(23):7476-82. PubMed ID: 2147578
[TBL] [Abstract][Full Text] [Related]
9. Delivery of aclacinomycin A to human glioma cells in vitro by the low-density lipoprotein pathway.
Rudling MJ; Collins VP; Peterson CO
Cancer Res; 1983 Oct; 43(10):4600-5. PubMed ID: 6309372
[TBL] [Abstract][Full Text] [Related]
10. Low density lipoprotein and liposome mediated uptake and cytotoxic effect of N4-octadecyl-1-beta-D-arabinofuranosylcytosine in Daudi lymphoma cells.
Koller-Lucae SK; Schott H; Schwendener RA
Br J Cancer; 1999 Jul; 80(10):1542-9. PubMed ID: 10408395
[TBL] [Abstract][Full Text] [Related]
11. Low-density lipoprotein as a carrier of antitumoral drugs: in vivo fate of drug-human low-density lipoprotein complexes in mice.
Masquelier M; Vitols S; Peterson C
Cancer Res; 1986 Aug; 46(8):3842-7. PubMed ID: 3731059
[TBL] [Abstract][Full Text] [Related]
12. MR and fluorescent imaging of low-density lipoprotein receptors.
Li H; Gray BD; Corbin I; Lebherz C; Choi H; Lund-Katz S; Wilson JM; Glickson JD; Zhou R
Acad Radiol; 2004 Nov; 11(11):1251-9. PubMed ID: 15561572
[TBL] [Abstract][Full Text] [Related]
13. LDL-mediated drug targeting.
de Smidt PC; van Berkel TJ
Crit Rev Ther Drug Carrier Syst; 1990; 7(2):99-120. PubMed ID: 2272100
[TBL] [Abstract][Full Text] [Related]
14. Native and acetylated low density lipoprotein metabolism in proliferating and quiescent bovine endothelial cells in culture.
Sanan DA; Strümpfer AE; van der Westhuyzen DR; Coetzee GA
Eur J Cell Biol; 1985 Jan; 36(1):81-90. PubMed ID: 3979404
[TBL] [Abstract][Full Text] [Related]
15. Preparation of low density lipoprotein-9-methoxy-ellipticin complex and its cytotoxic effect against L1210 and P 388 leukemic cells in vitro.
Samadi-Baboli M; Favre G; Blancy E; Soula G
Eur J Cancer Clin Oncol; 1989 Feb; 25(2):233-41. PubMed ID: 2702978
[TBL] [Abstract][Full Text] [Related]
16. Potential role of the low-density lipoprotein receptor family as mediators of cellular drug uptake.
Chung NS; Wasan KM
Adv Drug Deliv Rev; 2004 May; 56(9):1315-34. PubMed ID: 15109771
[TBL] [Abstract][Full Text] [Related]
17. Cytotoxic effect of a lipophilic alkylating agent after incorporation into low density lipoprotein or emulsions: studies in human leukemic cells.
Masquelier M; Lundberg B; Peterson C; Vitols S
Leuk Res; 2006 Feb; 30(2):136-44. PubMed ID: 16085310
[TBL] [Abstract][Full Text] [Related]
18. [The cytotoxic effect of a low density lipoprotein delivered aclarubicin on leukemia cells].
Li W; Xi S; Zhang M
Zhonghua Xue Ye Xue Za Zhi; 2001 Dec; 22(12):636-8. PubMed ID: 16200711
[TBL] [Abstract][Full Text] [Related]
19. Preparation of anti-HIV-low-density lipoprotein complexes for delivery of anti-HIV drugs via the low-density lipoprotein pathways.
Sqalli-Houssaini H; Pierlot C; Kusnierz JP; Parmentier B; Martin-Nizard F; Lestavel-Delattre S; Tartar A; Fruchart JC; Sergheraert C; Duriez P
Biotechnol Ther; 1994; 5(1-2):69-85. PubMed ID: 7703834
[TBL] [Abstract][Full Text] [Related]
20. Hepatic cholesterol and bile acid synthesis, low-density lipoprotein receptor function, and plasma and fecal sterol levels in mice: effects of apolipoprotein E deficiency and probucol or phytosterol treatment.
Moghadasian MH; Nguyen LB; Shefer S; Salen G; Batta AK; Frohlich JJ
Metabolism; 2001 Jun; 50(6):708-14. PubMed ID: 11398149
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
